The combination of cabozantinib and atezolizumab has antitumor activity and a manageable safety profile in men with metastatic castration-resistant prostate cancer, indicate preliminary trial data.
The patient-reported outcomes from the CARD trial of third-line cabazitaxel in men with metastatic castration-resistant prostate cancer add support for using the taxane in this setting, say researchers.
The 8-year results from the phase 3 CHHiP trial have confirmed the noninferiority of moderately hypofractionated radiotherapy delivering 60 Gy in 20 fractions to the conventional regimen for the control of localized prostate cancer.
Metastasis-directed therapy for oligometastatic recurrent prostate cancer continues to be associated with better androgen deprivation therapy-free survival relative to surveillance at 5 years, show follow-up findings from the STOMP trial.
Combining a single nucleotide polymorphism-based genetic risk score for prostate cancer with family history could improve the stratification of inherited risk and help personalize screening strategies, research suggests.